Neutrophil-lymphocyte ratio in Crohn’s disease patients predicts sustained response to infliximab 52-week therapy

Authors

  • Marcin K. Wlodarczyk Department of Gastroenterology, Medical University of Lodz, Lodz, Poland
  • Aleksandra E. Sobolewska Department of Gastroenterology, Medical University of Lodz, Lodz, Poland
  • Krystyna Stec-Michalska Department of Gastroenterology, Medical University of Lodz, Lodz, Poland
  • Jakub J. Fichna Department of Biochemistry, Medical University of Lodz, Lodz, Poland
  • Maria E. Wisniewska-Jarosinska Department of Gastroenterology, Medical University of Lodz, Lodz, Poland

Keywords:

.

Abstract

.

Downloads

Published

2015-03-01

How to Cite

1.
Wlodarczyk MK, Sobolewska AE, Stec-Michalska K, Fichna JJ, Wisniewska-Jarosinska ME. Neutrophil-lymphocyte ratio in Crohn’s disease patients predicts sustained response to infliximab 52-week therapy. JGLD [Internet]. 2015 Mar. 1 [cited 2026 Jun. 3];24(1):125-30. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/1261

Issue

Vol. 24 No. 1: March 2015

Section

Letters